Abstract 396P
Background
This study aims to describe clinical outcomes and characteristics of patients diagnosed with platinum-resistant recurrent ovarian cancer (PRROC) in a real-world setting. The study serves as a foundation for refining treatment strategies in the future.
Methods
The study included 504 patients who were diagnosed with PRROC from six tertiary hospitals in China during January 2018 and December 2023, and evaluated the characteristics, treatment patterns and outcomes of these people. In addition, background factors of patients were identified, and independent prognostic factors for OS were investigated.
Results
In this cohort of 504 patients diagnosed with PRROC, the most common regimen was single-agent chemotherapy(54.96%). Compared to single-agent nonplatinum chemotherapy group, platinum-based combination chemotherapy group showed signifcantly longer PFS (5.6 vs. 4.0 months; p<0.0001)and OS (15.9 vs. 13.0 months; p=0.0057). Although not statistically signifcant, PARPi monotherapy group tended to improve PFS(4.5 vs. 4.0 months; p=0.15) and OS(13.1 vs. 13.0 months; p=0.56) compared with single-agent nonplatinum chemotherapy group. Improvements in efficiencies were observed after adding antiangiogenic therapy to platinum-based combination chemotherapy and single-agent nonplatinum chemotherapy. The independent prognostic factor for OS was progression-free interval (PFI), histology type and clinical trial participation. In the subgroup of patients received platinum-based combination chemotherapy, patients with PFI 3-6 months retreated with platinum based chemotherapy had longer OS when compared to patients with PFI 3-6 months (16.47 months vs 12.83 months, 95% CI: 1.149–2.006, P=0.0044).
Conclusions
In this real-world cohort, patients diagnosed with PRROC, particularly in patients with PFI 3-6 months, may experience substantial benefits from the re-administration of platinum agents. Entrying onto an early-phase trial of a new drug or combination is also a promising option for PRROC patients, meanwhile, challengeing clinical trial design and criteria for patient selection are an important area of focus.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Q. Wang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.